Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patients with venous thromboembolism is unclear. METHODS: In a randomized, double-blind, noninferiority study, we randomly assigned patients with acute venous thromboembolism, who had initially received heparin, to receive edoxaban at a dose of 60 mg once daily, or 30 mg once daily (e.g., in the case of patients with creatinine clearance of 30 to 50 ml per minute or a body weight below 60 kg), or to receive warfarin. Patients received the study drug for 3 to 12 months. The primary efficacy outcome was recurrent symptomatic venous thromboembolism. The principal safety outcome was major or clinically relevant nonmajor bleeding. RESULTS: A total of 4921 patients presented with deep-vein thrombosis, and 3319 with a pulmonary embolism. Among patients receiving warfarin, the time in the therapeutic range was 63.5%. Edoxaban was noninferior to warfarin with respect to the primary efficacy outcome, which occurred in 130 patients in the edoxaban group (3.2%) and 146 patients in the warfarin group (3.5%) (hazard ratio, 0.89; 95% confidence interval [CI], 0.70 to 1.13; P<0.001 for noninferiority). The safety outcome occurred in 349 patients (8.5%) in the edoxaban group and 423 patients (10.3%) in the warfarin group (hazard ratio, 0.81; 95% CI, 0.71 to 0.94; P=0.004 for superiority). The rates of other adverse events were similar in the two groups. A total of 938 patients with pulmonary embolism had right ventricular dysfunction, as assessed by measurement of N-terminal pro-brain natriuretic peptide levels; the rate of recurrent venous thromboembolism in this subgroup was 3.3% in the edoxaban group and 6.2% in the warfarin group (hazard ratio, 0.52; 95% CI, 0.28 to 0.98). CONCLUSIONS: Edoxaban administered once daily after initial treatment with heparin was noninferior to high-quality standard therapy and caused significantly less bleeding in a broad spectrum of patients with venous thromboembolism, including those with severe pulmonary embolism. (Funded by Daiichi-Sankyo; Hokusai-VTE ClinicalTrials.gov number, NCT00986154.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
SCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
SCHULMAN, S., ANGERÅS, U., BERGQVIST, D., ERIKSSON, B., LASSEN, M. R., & FISHER, W. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03678.x · Cited by 3,756
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Self-citationDabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
Büller (2012) · doi:10.1056/nejmoa1113572 · Cited by 2,353
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Masiukiewicz, U., Pak, R., Thompson, J., Raskob, G. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302507 · Cited by 2,324
The Epidemiology of Venous Thromboembolism
White, R. H. (2003) · Circulation · doi:10.1161/01.cir.0000078468.11849.66 · Cited by 2,310
A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy
Rosendaal, F. R., Cannegieter, S. C., van der Meer, F. J. M., & Briët, E. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651587 · Cited by 2,065
Pulmonary embolism and deep vein thrombosis
Goldhaber, S. Z., & Bounameaux, H. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61904-1 · Cited by 1,054
Cited by
Items 401–500 of 1,001
Severe renal impairment and risk of bleeding during anticoagulation for venous thromboembolism
Catella, J., Bertoletti, L., Mismetti, P., Ollier, É., Samperiz, A. L., Soler, S., Suriñach, J. M., Mahé, I., Lorente, M. A., Braester, A., et al. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14837 · Cited by 34
Chazova, I. E., Ageev, F. T., Владимировна, А. А., Vicenya, M. V. V., Gilyarov, M. Y., Martynyuk, T. V., Панченко, Е. П., Poltavskaya, M. G., Potievskaya, V. I., Trofimova, O. P., et al. (2022) · Eurasian heart journal · doi:10.38109/2225-1685-2022-1-6-79 · Cited by 36
Wu, C. M., Alotaibi, G., AlSaleh, K. A., & McMurtry, M. S. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.07.001 · Cited by 34
Mukdad, M. A., Al‐Badriyeh, D., & Elewa, H. F. (2019) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029619849103 · Cited by 34
Safety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism
Giustozzi, M., Franco, L., Vedovati, M. C., Becattini, C., & Agnelli, G. (2019) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-019-01878-x · Cited by 38
Thromboembolism in Older Adults
Gross, P. L., & Chan, N. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2020.470016 · Cited by 36
“The median age of subjects in these studies was between 55 and 60 years of age; the edoxaban study (82) reported that about 15% of patients were aged ≥75.”
BackgroundThrombosis and Aging: Fibrin Clot Properties and Oxidative Stress
Konieczyńska, M., Natorska, J., & Undas, A. (2024) · Antioxidants and Redox Signaling · doi:10.1089/ars.2023.0365 · Cited by 40
“In contrast to warfarin, age > 75 years did not increase the bleeding rates in rivaroxaban-treated patients (Agnelli et al., 2013; Buller et al., 2013; Prins et al., 2013; Schulman et al., 2014).”
Amin, A., Bruno, A. S., Trocio, J. N., Lin, J., & Lingohr-Smith, M. (2015) · Journal of Medical Economics · doi:10.3111/13696998.2015.1007210 · Cited by 37
Weitz, J. I., Jaffer, I., & Fredenburgh, J. C. (2017) · F1000Research · doi:10.12688/f1000research.11174.1 · Cited by 40
Clinical outcomes during anticoagulant therapy in fragile patients with venous thromboembolism
Moustafa, F., Giorgi‐Pierfranceschi, M., Micco, P. D., Bucherini, E., Lorenzo, A., Villalobos, A., Nieto, J. A., Valero, B., Samperiz, A. L., Monréal, M., et al. (2017) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12036 · Cited by 34
Direct oral anticoagulants: An update
Franco‐Moreno, A., Díaz, R. M. M., & Navarro, M. J. G. (2018) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2018.07.005 · Cited by 34
Riess, H. B., Ay, C., Bauersachs, R. M., Becattini, C., Beyer‐Westendorf, J., Cajfinger, F., Chau, I., Cohen, A. T., Khorana, A. A., Maraveyas, A., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0473 · Cited by 33
Caterina, R. D., Kelly, P. J., Monteiro, P. F., Deharo, J., de Asmundis, C., de Sá, E. L., Weiss, T. W., Waltenberger, J. L., Steffel, J., de Groot, J. R., et al. (2018) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000000737 · Cited by 34
Kubo, K., Kato, M., Mabe, K., Harada, N., Iboshi, Y., Kagaya, T., Ono, M., Toyokawa, T., Yamashita, H., Kuwai, T., et al. (2019) · Digestion · doi:10.1159/000502952 · Cited by 31
Unanswered questions in cancer‐associated thrombosis
Sanfilippo, K. M., Moik, F., Candeloro, M., Ay, C., Nisio, M. D., & Lee, A. Y. Y. (2022) · British Journal of Haematology · doi:10.1111/bjh.18276 · Cited by 32
He, L., Kochan, J. P., Lin, M., Vandell, A. G., Brown, K. S., & Depasse, F. (2017) · Thrombosis Research · doi:10.1016/j.thromres.2017.05.005 · Cited by 31
Preclinical and clinical data for factor Xa and “universal” reversal agents
Milling, T. J., & Kaatz, S. (2016) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2016.09.052 · Cited by 32
Anticoagulation of Cardiovascular Conditions in the Cancer Patient: Review of Old and New Therapies
Rhea, I. B., Lyon, A. R., & Fradley, M. G. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0797-z · Cited by 30
Barbui, T., Stefano, V. D., Falanga, A., Finazzi, G., Martinelli, I., Rodeghiero, F., Vannucchi, A. M., & Barosi, G. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0225-5 · Cited by 32
Loffredo, L., Violi, F., & Perri, L. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.03.086 · Cited by 31
Vanassche, T., Verhamme, P. B., Wells, P. S., Segers, A. E. M., Ageno, W., Brekelmans, M. P. A., Chen, C. Z., Cohen, A. T., GROSSO, M. A., Medina, A., et al. (2017) · Thrombosis Research · doi:10.1016/j.thromres.2017.12.005 · Cited by 35
Age‐adjusted D‐dimer cutoff for the diagnosis of pulmonary embolism: A cost‐effectiveness analysis
Blondon, M., Gal, G. L., Meyer, G., Righini, M., & Robert‐Ebadi, H. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14733 · Cited by 31
Novel antidotes for target specific oral anticoagulants
Das, A., & Liu, D. (2015) · Experimental Hematology and Oncology · doi:10.1186/s40164-015-0020-3 · Cited by 36
“Edoxaban has most recently joined the rest [6, 7].”
BackgroundConsistency of safety profile of new oral anticoagulants in patients with renal failure
Lega, J., Bertoletti, L., Gremillet, C., Boissier, C., Mismetti, P., & Laporte, S. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12486 · Cited by 29
Assessment of coronary artery disease during hospitalization for cancer treatment
Mrotzek, S. M., Lena, A., Hadzibegovic, S., Ludwig, R., Al‐Rashid, F., Mahabadi, A. A., Mincu, R. I., Michel, L., Johannsen, L., Hinrichs, L., et al. (2020) · Clinical Research in Cardiology · doi:10.1007/s00392-020-01719-5 · Cited by 35
Suzuki, H., Matsuzawa, Y., Konishi, M., Akiyama, E., Takano, K., Nakayama, N., Kataoka, S., Ebina, T., Kosuge, M., Hibi, K., et al. (2014) · Circulation Journal · doi:10.1253/circj.cj-13-1325 · Cited by 29
Schellong, S., Kakkar, A. K., Eriksson, H., Feuring, M., Kreuzer, J., Fraessdorf, M., Schulman, S., & Goldhaber, S. Z. (2016) · Thrombosis and Haemostasis · doi:10.1160/th16-04-0271 · Cited by 34
Nishimoto, Y., Yamashita, Y., Morimoto, T., Saga, S., Amano, H., Takase, T., Hiramori, S., Kim, K., Oi, M., Akao, M., et al. (2019) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14691 · Cited by 32
Kang, J. M., Park, K. H., Ahn, S., Cho, S., Han, A., Lee, T., Jung, I. M., Kim, J. Y., & Min, S. (2019) · Scientific Reports · doi:10.1038/s41598-019-56887-w · Cited by 29
Kawamatsu, N., Ishizu, T., Machino‐Ohtsuka, T., Masuda, K., Horigome, H., Takechi, F., Tateno, S., Fukuda, T., Kijima, Y., Shiina, Y., et al. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.11.024 · Cited by 33
Prevention of venous thromboembolism in ambulatory patients with cancer
Khorana, A. A., Cohen, A. T., Carrier, M., Meyer, G., Pabinger, I., Kavan, P., & Wells, P. S. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000948 · Cited by 32
Preblick, R., Kwong, W. J., White, R. H., & Goldhaber, S. Z. (2015) · Hospital Practice · doi:10.1080/21548331.2015.1099412 · Cited by 28
“Sources: Resource use data are from a post hoc analysis of the Hokusai-VTE study [5]; cost data are from an analysis of the Premier Hospital Database 2009–2011.”
BackgroundMethodInfluentialDiretriz de Avaliação Cardiovascular Perioperatória da Sociedade Brasileira de Cardiologia – 2024
Gualandro, D. M., Fornari, L. S., Caramelli, B., Abizaid, A., Gomes, B. R., Tavares, C. A. M., Fernandes, C. J. C. D. S., Polanczyk, C. A., Jardim, C., Vieira, C. L. Z., et al. (2024) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20240590 · Cited by 43
A Comprehensive Overview of Direct Oral Anticoagulants for the Management of Venous Thromboembolism
Comerota, A. J., & Ramacciotti, E. (2016) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2016.03.018 · Cited by 29
“Edoxaban was shown to be superior to VKAs in patients with submassive PE following a predefined subset analysis.(55) This is the first observation that patients with advanced VTE are more effectively treated with a DOAC than with conventional anticoagulation.”
Direct oral anticoagulants: an alternative treatment for thrombotic antiphospholipid syndrome?
Rességuier, A.-S., Pereira, B., Rieu, V., Guenno, G. L., Grobost, V., & Ruivard, M. (2017) · Lupus · doi:10.1177/0961203317701841 · Cited by 30
Direct oral anticoagulants for treatment and prevention of venous thromboembolism in cancer patients
Song, A. B., Rosovsky, R. P. G., Connors, J. M., & Al-Samkari, H. T. (2019) · Vascular Health and Risk Management · doi:10.2147/vhrm.s132556 · Cited by 29
Extended anticoagulation after venous thromboembolism: should it be done?
Fernandes, C. J. C. D. S., Calderaro, D., Piloto, B. M., Hoette, S., Jardim, C., & Souza, R. (2019) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466619878556 · Cited by 28
36-month clinical outcomes of patients with venous thromboembolism: GARFIELD-VTE
Turpie, A. G. G., Farjat, A. E., Haas, S. K., Ageno, W., Weitz, J. I., Goldhaber, S. Z., Goto, S., Angchaisuksiri, P., Kayani, G., Lópes, R. D., et al. (2022) · Thrombosis Research · doi:10.1016/j.thromres.2022.11.016 · Cited by 28
Hosokawa, K., Abe, K., Funakoshi, K., Tamura, Y., Nakashima, N., Todaka, K., Taniguchi, Y., Inami, T., Adachi, S., Tsujino, I., et al. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.03.036 · Cited by 30
Palareti, G. (2014) · Seminars in Hematology · doi:10.1053/j.seminhematol.2014.02.002 · Cited by 29
Anticoagulant treatment for acute pulmonary embolism: a pathophysiology-based clinical approach
Agnelli, G., & Becattini, C. (2015) · European Respiratory Journal · doi:10.1183/09031936.00164714 · Cited by 33
Ageno, W., Mantovani, L. G., Haas, S. K., Kreutz, R. H., Haupt, V., Schneider, J., & Turpie, A. G. (2014) · Thrombosis Journal · doi:10.1186/1477-9560-12-16 · Cited by 29
The new oral anticoagulants: Reasonable alternatives to warfarin
Roca, B., & Roca, M. (2015) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.82a.14052 · Cited by 28
Singer, A. J., Quinn, A., Dasgupta, N., & Thode, H. C. (2016) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2016.09.028 · Cited by 33
Moustafa, F., Pesavento, R., Micco, P. D., González‐Martínez, J., Quintavalla, R., Peris, M. L., Porras, J. A., Falvo, N., Baños, P., Monréal, M., et al. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.781 · Cited by 30
Self-citationLam, E., Bashir, B., Chaballa, M., & Kraft, W. K. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1637733 · Cited by 27
Cerebral and Splanchnic Vein Thrombosis: Advances, Challenges, and Unanswered Questions
Riva, N., & Ageno, W. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9030743 · Cited by 29
Colonna, P., von Heymann, C., Santamaría, A., Saxena, M., Vanassche, T., Wolpert, D., Laeis, P., Wilkins, R. G., Chen, C. Y.-H., & Unverdorben, M. (2020) · Clinical Cardiology · doi:10.1002/clc.23379 · Cited by 32
“Previous studies with edoxaban have demonstrated noninferiority to warfarin for stroke prevention in AF and for VTE treatment/secondary prevention of thromboembolic events and shown a reduced MB or clinically relevant non-major bleeding (CRNMB) incidence, and in particular a lower incidence of potentially life-threate…”
ResultLutsey, P. L., Walker, R. F., MacLehose, R. F., Norby, F. L., Evensen, L. H., Alonso, Á., & Zakai, N. A. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.020428 · Cited by 31
Fifty years of research on antithrombotic therapy: Achievements and disappointments
Hirsh, J., Eikelboom, J. W., & Chan, N. (2019) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2019.10.023 · Cited by 29
Cancer‐associated thrombosis and drug–drug interactions of antithrombotic and antineoplastic agents
Bölek, H., & Ürün, Y. (2023) · Cancer · doi:10.1002/cncr.34937 · Cited by 30
Niebecker, R., Jönsson, S., Karlsson, M. O., Miller, R., Nyberg, J., Krekels, E. H. J., & Simonsson, U. S. H. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12727 · Cited by 26
Bleeding events with dabigatran or warfarin in patients with venous thromboembolism
Goldhaber, S. Z., Kakkar, A. K., Kearon, C., Eriksson, H., Kreuzer, J., Feuring, M., Hantel, S., Friedman, J. E., Schellong, S., Schulman, S., et al. (2015) · Thrombosis and Haemostasis · doi:10.1160/th15-04-0319 · Cited by 26
Song, S., Kang, D., Halim, A., & Miller, R. (2014) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.306 · Cited by 26
Ageno, W., Mantovani, L. G., Haas, S. K., Kreutz, R. H., Monje, D., Schneider, J., van Eickels, M., Gebel, M., & Turpie, A. G. G. (2017) · TH Open · doi:10.1055/s-0037-1603924 · Cited by 26
Bleeding in patients receiving non-vitamin K oral anticoagulants: clinical trial evidence
Bracey, A., Shatila, W., & Wilson, J. M. (2018) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944718801554 · Cited by 31
DIRECT ORAL ANTICOAGULANTS IN PATIENTS AFFECTED BY MAJOR CONGENITAL THROMBOPHILIA
Serrao, A., Lucani, B., Mansour, D., Ferretti, A., Baldacci, E., Santoro, C., Foà, R., & Chistolini, A. (2019) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2019.044 · Cited by 27
“Median FU during DOACs (months) 29 (6-66)”
BackgroundEthnoracial variations in venous thrombosis: Implications for management, and a call to action
Xu, Y., Siegal, D. M., & Anand, S. S. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15140 · Cited by 28
Perino, A. C., Fan, J., Schmitt, S. K., Guo, J. D., Hlavacek, P., Din, N., Kothari, M., Pundi, K. N., Russ, C., Emir, B., et al. (2021) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.121.008005 · Cited by 26
“Separately, we stratified patients into the following BMI categories: (1) <25 kg/ m2, (2) ≥25 to <30 kg/m2, (3) ≥30 to <35 kg/m2, (4) ≥35 to <40 kg/m2, (5) ≥40 to <50 kg/m2, and (6) ≥50 kg/m2.”
InfluentialDirect oral anticoagulants for use in paediatrics
Jaffray, J., & Young, G. (2022) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(21)00343-6 · Cited by 29
Thompson, L. E., Davis, B. H., Narayan, R., Goff, B., Brown, T. M., & Limdi, N. A. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2714 · Cited by 28
“12,14– 16 Edoxaban was the only DOAC with a safety profile that differed by gender, being safer than warfarin in reducing major and clinically relevant nonMB in men, but demonstrating only a similar safety profile to warfarin in women.(17) REVIEW”
BackgroundBackus, B. E., Beyer‐Westendorf, J., Body, R. M., Lindner, T., Möckel, M., Sehgal, V., Parry‐Jones, A., Seiffge, D. J., & Gibler, B. (2023) · European Journal of Emergency Medicine · doi:10.1097/mej.0000000000001049 · Cited by 33
Prandoni, P., Barbar, S., Milan, M., Vedovetto, V., & Pesavento, R. (2013) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2013.09.005 · Cited by 26
“addressing the value of edoxaban have recently become available [79].”
BackgroundDiagnose und Management der akuten pulmonalen Embolie: ESC-Leitlinien 2014
Saar, J. A., & Maack, C. (2015) · Herz · doi:10.1007/s00059-015-4378-0 · Cited by 30
Kalathottukaren, M. T., Haynes, C. A., & Kizhakkedathu, J. N. (2017) · Drug Delivery and Translational Research · doi:10.1007/s13346-017-0413-4 · Cited by 26
What have we learned from real-world NOAC studies in venous thromboembolism treatment?
Beyer‐Westendorf, J. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.01.034 · Cited by 28
Yamashita, Y., Morimoto, T., Toyota, T., Shiomi, H., Makiyama, T., Ono, K., & Kimura, T. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.04.008 · Cited by 30
Bertoletti, L., Benhamou, Y., Béjot, Y., Maréchaux, S., Cheggour, S., Aleil, B., Lellouche, N., Dillinger, J., & Delluc, A. (2018) · Blood Reviews · doi:10.1016/j.blre.2018.01.002 · Cited by 30
Kraaijpoel, N., van Es, N., Raskob, G. E., Buller, H. R., Carrier, M., Zhang, G., Lin, M., GROSSO, M. A., & Nisio, M. D. (2018) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1649523 · Cited by 28
Ohashi, Y., Ikeda, M., Kunitoh, H., Sasako, M., Okusaka, T., Mukai, H., Fujiwara, K., Nakamura, M., Kimura, T., Ibusuki, K., et al. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-018910 · Cited by 26
Cáliz, R., Fontecha, P. D. D. C., Galindo-Izquierdo, M., Longo, F. J. L., Zamora, M. Á. M., Santamaría, A., Pliego, O. A., Lozano, M. J. C., Beltrán, M. P. D., Carmona, L., et al. (2019) · Reumatología Clínica · doi:10.1016/j.reuma.2018.11.003 · Cited by 34
Use of direct‐acting oral anticoagulants in solid organ transplantation: A systematic review
Bixby, A. L., Lichvar, A. B., Salerno, D. M., & Park, J. M. (2020) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2485 · Cited by 26
Weitz, J. I., & Jaffer, I. (2016) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.3547 · Cited by 28
Management of intermediate‐risk pulmonary embolism: uncertainties and challenges
Klok, F. A., Meyer, G., & Konstantinides, S. (2015) · European Journal Of Haematology · doi:10.1111/ejh.12612 · Cited by 27
Recent developments in the diagnosis and treatment of pulmonary embolism
van der Hulle, T., Dronkers, C. E. A., Klok, F. A., & Huisman, M. V. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12404 · Cited by 28
New Trends in Anticoagulation Therapy
SMITH, M. H. D., Wakam, G. K., Wakefield, T. W., & Obi, A. T. (2018) · Surgical Clinics of North America · doi:10.1016/j.suc.2017.11.003 · Cited by 26
Coulis, A. A., & Mackey, W. C. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.10.009 · Cited by 27
Recio‐Boiles, A., Veeravelli, S., Vondrak, J., Babiker, H. M., Scott, A. J., Shroff, R. T., Patel, H., Elquza, E., & McBride, A. (2019) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v11.i10.866 · Cited by 25
Covert, K. L., & Branam, D. L. (2020) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa059 · Cited by 26
“8%) in the edoxaban group weighed more than 100 kg, and the investigators did not evaluate the impact of body weight on safety or efficacy outcomes.(9) There have been no pharmaco-”
BackgroundTreatment of Venous Thromboembolism in Special Populations with Direct Oral Anticoagulants
Bavalia, R., Middeldorp, S., Weißer, G., & Espinola–Klein, C. (2020) · Thrombosis and Haemostasis · doi:10.1055/s-0040-1710314 · Cited by 26
Inclusion of Older People Reflective of Real‐World Clinical Practice in Cardiovascular Drug Trials
Caughey, G. E., Inacio, M. C. S., Bell, J. S., Vitry, A. I., & Shakib, S. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.016936 · Cited by 26
Klok, F. A., Toenges, G., Mavromanoli, A. C., Barco, S., Ageno, W., Bouvaist, H., Brodmann, M., Cuccia, C., Couturaud, F., Dellas, C., et al. (2021) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00203-9 · Cited by 31
Shaikh, F., Wynne, R. M., Castelino, R. L., Inglis, S. C., & Ferguson, C. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.732828 · Cited by 26
Amin, A., & Marrs, J. C. (2016) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029615601492 · Cited by 29
“Extended anticoagulation (>3 months) is beneficial in patients with VTE, and the direct OACs have demonstrated noninferiority in the reduction of recurrent venous thromboembolic events versus standard therapy.(26,27,29,32,33,36,38,39) Phase II dose-finding studies of anticoagulants usually focus on safety outcomes to…”
BackgroundNovel anticoagulants and antiplatelet agents; a guide for the urologist
Ellis, G., Camm, A. J., & Datta, S. N. (2015) · British Journal of Urology · doi:10.1111/bju.13131 · Cited by 26
DVT Management and Outcome Trends, 2001 to 2014
Morillo, R., Jiménez, D., Arregui, M. Á. A., Mastroiacovo, D., Wells, P. S., Samperiz, A. L., de Sousa, M. S., Muriel, A., Yusen, R. D., Monréal, M., et al. (2016) · CHEST Journal · doi:10.1016/j.chest.2016.03.046 · Cited by 26
Direct-Acting Oral Anticoagulants: Practical Considerations for Emergency Medicine Physicians
Peacock, W. F., Rafique, Z., & Singer, A. J. (2016) · Emergency Medicine International · doi:10.1155/2016/1781684 · Cited by 28
Anticoagulant Preferences and Concerns among Venous Thromboembolism Patients
Lutsey, P. L., Horvath, K. J., Fullam, L., Moll, S., Rooney, M. R., Cushman, M., & Zakai, N. A. (2018) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1625985 · Cited by 28
Clinically relevant non-major bleeding with oral anticoagulants: non-major may not be trivial.
Franco, L., Becattini, C., Vanni, S., Sbrojavacca, R., Nitti, C., Manina, G., Masotti, L., Pomero, F., Cattinelli, S., Cappelli, R., et al. (2018) · Blood transfusion · doi:10.2450/2017.0335-16 · Cited by 26
New Anticoagulant Agents: Incidence of Adverse Drug Reactions and New Signals Thereof
Jiménez-Serranía, M.-I., Martínez-García, R., Corzo-Delibes, F., Arias, L. M., & Lobato, C. T. (2018) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0038-1657783 · Cited by 25
Current Antithrombotic Treatments for Cardiovascular Diseases: A Comprehensive Review
Galanti, K., Marino, M. D., Mansour, D., Testa, S., Rossi, D., Scollo, C., Magnano, R., Pezzi, L., D’Alleva, A., Forlani, D., et al. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2508281 · Cited by 27
Population Pharmacokinetics and Dose–Exposure Proportionality of Edoxaban in Healthy Volunteers
Yin, O. Q. P., & Miller, R. (2014) · Clinical Drug Investigation · doi:10.1007/s40261-014-0229-7 · Cited by 24
“In phase III trials in patients with non-valvular AF [5] or patients with acute deep vein thrombosis and/or pulmonary embolism [6], no notable difference was observed in both primary efficacy and safety measures between male and female patients.”
BackgroundMethodTreatment options for venous thromboembolism: lessons learnt from clinical trials
McRae, S. J. (2014) · Thrombosis Journal · doi:10.1186/s12959-014-0027-8 · Cited by 26
Pharmacology and Laboratory Testing of the Oral Xa Inhibitors
Samama, M. M., Meddahi, S., & Samama, C. M. (2014) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2014.06.009 · Cited by 26
Willett, K. C., & Morrill, A. M. (2017) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s88911 · Cited by 24
Pulmonary embolism response teams
Serhal, M., Haddadin, I., Heresi, G. A., Hornacek, D., Shishehbor, M. H., & Bartholomew, J. R. (2017) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-017-1498-9 · Cited by 28
Rudà, R., on behalf of the SINch Neuro-Oncology Section, A. A. S. N.-O. S., Angileri, F. F., Ius, T., Silvani, A., Sarubbo, S., Solari, A., Castellano, A., Falini, A., Pollo, B., et al. (2020) · Journal of Neurosurgical Sciences · doi:10.23736/s0390-5616.20.04982-6 · Cited by 25
Direct Oral Anticoagulants in Cancer Patients. Time for a Change in Paradigm
Wojtukiewicz, M. Z., Skalij, P., Tokajuk, P., Polityńska, B., Wojtukiewicz, A. M., Tucker, S. C., & Honn, K. V. (2020) · Cancers · doi:10.3390/cancers12051144 · Cited by 24
Balancing ischaemia and bleeding risks with novel oral anticoagulants
Baber, U., Mastoris, I., & Mehran, R. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.170 · Cited by 29
Chatani, R., Yamashita, Y., Morimoto, T., Mushiake, K., Kadota, K., Kaneda, K., Nishimoto, Y., Ikeda, N., Kobayashi, Y., Ikeda, S., et al. (2024) · Thrombosis Research · doi:10.1016/j.thromres.2023.12.016 · Cited by 24
Metadata
- Authors
- The Hokusai-VTE Investigators
- Corresponding author
- The Hokusai-VTE Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-10-10
- Volume
- 369
- Issue
- 15
- Pages
- 1406-1415
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2160625453
- Cited by
- 1,869
- References
- 25
- Citations by year
- 2026: 52 · 2025: 75 · 2024: 112 · 2023: 104 · 2022: 116 · 2021: 128 · 2020: 179 · 2019: 170 · 2018: 190 · 2017: 173 · 2016: 210 · 2015: 173 · 2014: 161 · 2013: 25
- FWCI
- 165.78
- Type
- journal article
- Language
- en
- Open access
- Licence
- other-oa
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, other-oa)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- IRIS (submittedVersion)
- Institutional Research Information System (Università degli Studi di Trento) (submittedVersion)
- Iris (University of Trento) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Pfizer
- GlaxoSmithKline
- Sanofi
- Daiichi-Sankyo
- LEO Pharma
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- warfarin, venous thromboembolism, factor Xa inhibitors, deep vein thrombosis, pulmonary embolism, recurrent venous thromboembolism, non-inferiority, bleeding risk, right ventricular dysfunction, N-terminal pro-brain natriuretic peptide, anticoagulation, heparin, renal dysfunction, body weight
- MeSH terms
- Aged, Anticoagulants, Double-Blind Method, Drug Administration Schedule, Female, Hemorrhage, Humans, Male, Middle Aged, Pulmonary Embolism, Warfarin, Enoxaparin, Kaplan-Meier Estimate, Venous Thromboembolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.